16 October 2018
LNC Therapeutics acquires exclusive license for the Christensenella patent from Cornell University
LNC aims to develop the first Christensenella-based drug candidate for the treatment of obesity and metabolic disorders
Search
LNC aims to develop the first Christensenella-based drug candidate for the treatment of obesity and metabolic disorders